title: Region-specific upregulation of parvalbumin-, but not calretinin-positive cells in the ventral hippocampus during adolescence.
abstract: Animal studies have highlighted the role of the ventral hippocampus-prefrontal cortex pathway in the acquisition of mature cortical function through refinement of GABAergic circuits during adolescence. Inhibitory GABAergic responses are mediated by highly specialized interneurons, which have distinct functional properties and are characterized by the expression of calcium binding proteins. Among these, we recently found that parvalbumin (PV)- and calretinin (CR)-positive interneurons in the prefrontal cortex follow opposite developmental trajectories during the periadolescent transition period. In the present study, we asked whether interneurons expressing PV and CR in the ventral hippocampus follow similar periadolescent trajectories as seen in the prefrontal cortex. By measuring the relative abundance of these interneurons in three age groups (postnatal days (PD) 25-40, 45-55, and 60-85), we found that regions within the dorso-ventral axis of the ventral hippocampus undergo distinct developmental trajectories in PV expression during the periadolescent transition. Specifically, the ventral subiculum displayed a dramatic increase in PV-positive interneurons from PD25-40 to PD45-55 with an increasing rostro-caudal gradient, whereas negligible changes were found in the dorsal and middle regions. In contrast, the number of CR-positive interneurons in the ventral hippocampus remained unchanged across the three age groups studied. Together, these results describe for the first time that GABAergic circuits in the ventral hippocampus undergo protracted development during adolescence, in particular the PV-positive cell population circumscribed to the ventral region of the ventral hippocampus.
authors.affiliation: Department of Cellular and Molecular Pharmacology, The Chicago Medical School at Rosalind Franklin University of Medicine and Science, North Chicago, Illinois.
authors.forename: Adriana
authors.initials: A
authors.lastname: Caballero
authors.forename: Kimberly C
authors.initials: KC
authors.lastname: Diah
authors.forename: Kuei Y
authors.initials: KY
authors.lastname: Tseng
mesh_terms: D000367:Age Factors; D000704:Analysis of Variance; D000818:Animals; D000831:Animals, Newborn; D064032:Calbindin 2 / Q000378:metabolism*; D006624:Hippocampus / Q000166:cytology*; D008297:Male; D009474:Neurons / Q000378:metabolism*; D010320:Parvalbumins / Q000378:metabolism*; D051381:Rats; D017207:Rats, Sprague-Dawley; D015854:Up-Regulation / Q000502:physiology*
chemical_list: D064032:Calbindin 2; D010320:Parvalbumins
keywords: adolescence; calretinin; interneurons; parvalbumin; ventral hippocampus
references.citation: Eur J Neurosci. 2006 May;23(10):2581-94
references.pmid: 16817861
references.citation: J Psychiatr Res. 2005 Mar;39(2):117-27
references.pmid: 15589559
references.citation: Biol Psychiatry. 1999 Sep 1;46(5):616-26
references.pmid: 10472415
references.citation: Schizophr Res. 2002 May 1;55(1-2):1-10
references.pmid: 11955958
references.citation: Cereb Cortex. 2013 Jun;23(6):1396-409
references.pmid: 22615141
references.citation: Pharmacol Biochem Behav. 2009 Sep;93(3):212-21
references.pmid: 19593842
references.citation: Neurotox Res. 2010 Nov;18(3-4):367-76
references.pmid: 20143199
references.citation: Biol Psychol. 2000 Oct;54(1-3):241-57
references.pmid: 11035225
references.citation: Biol Psychiatry. 2005 Feb 1;57(3):252-60
references.pmid: 15691526
references.citation: Child Dev. 2010 Nov-Dec;81(6):1641-60
references.pmid: 21077853
references.citation: Nat Rev Neurosci. 2011 Sep 07;12(10):585-601
references.pmid: 21897434
references.citation: Curr Opin Neurobiol. 2009 Apr;19(2):220-30
references.pmid: 19481443
references.citation: J Neurosci. 2012 Aug 8;32(32):10915-24
references.pmid: 22875926
references.citation: Schizophr Bull. 2011 May;37(3):514-23
references.pmid: 21505118
references.citation: Biol Psychiatry. 2001 Jul 15;50(2):71-83
references.pmid: 11526998
references.citation: Schizophr Res. 2011 Sep;131(1-3):165-73
references.pmid: 21745723
references.citation: Am J Psychiatry. 2001 Mar;158(3):497-8
references.pmid: 11229999
references.citation: Behav Brain Res. 2009 Dec 7;204(2):295-305
references.pmid: 19100784
references.citation: Nat Neurosci. 1998 Aug;1(4):318-23
references.pmid: 10195166
references.citation: Neuropsychopharmacology. 2001 Jul;25(1):1-27
references.pmid: 11377916
references.citation: Nat Rev Neurosci. 2008 Dec;9(12):947-57
references.pmid: 19002191
references.citation: Trends Pharmacol Sci. 2011 Sep;32(9):507-13
references.pmid: 21700346
references.citation: J Neurosci. 2003 Nov 5;23(31):9987-95
references.pmid: 14602812
references.citation: Schizophr Bull. 2011 May;37(3):484-92
references.pmid: 21505115
references.citation: Br J Psychiatry. 1992 Feb;160:179-86
references.pmid: 1540757
references.citation: J Neural Transm (Vienna). 2002 May;109(5-6):891-905
references.pmid: 12111476
references.citation: J Neurosci. 2010 Feb 17;30(7):2547-58
references.pmid: 20164340
references.citation: Brain Struct Funct. 2014 Jan;219(1):395-406
references.pmid: 23400698